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Restoring blood flow is the most effective means to limit
damage to ischemic tissue. Since the 1960s, surgical place-
ment of bypass grafts for coronary artery disease (CAD) and
peripheral vascular disease has effectively and durably re-
stored blood flow to ischemic tissue. Nonsurgical revascu-
larization was introduced clinically starting in the 1970s.
Thrombolytic therapy is used to treat acute thrombotic
arterial occlusion. Angioplasty combined with stent place-
ment is currently the most frequently applied nonsurgical
method of relieving acute coronary ischemia.
Now, therapeutic angiogenesis, the promotion of new
vessel growth using vascular growth factors, is the latest and
perhaps most exciting strategy for revascularizing ischemic
tissue (1–4). Angiogenesis is induced by invasive (surgical or
catheter-based approaches) and noninvasive (intramuscular
or intra-arterial) delivery of a variety of promoters (5).
Vascular endothelial growth factor (VEGF) (6) and basic
fibroblastic growth factor (bFGF) (7) are the angiogenic
agents in most current clinical studies.
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Four isoforms of VEGF differing in numbers of amino
acids are known. The isoforms with 121 and 165 amino
acids (VEGF121 and VEGF165) are being used in human
investigations. Vascular endothelial growth factor avidly
binds to heparin with a half-life of about 6 min and causes
dose-dependent hypotension. Its actions are specific to
endothelial cells.
Basic fibroblastic growth factor also binds to heparin.
Unlike VEGF, it binds to receptors on fibroblasts and
vascular smooth muscle as well as endothelial cells. It has a
circulatory half-life of approximately 45 min and also causes
a dose-dependent hypotension.
The optimal way to package and deliver these agents is
uncertain. They can be given directly as the protein or
indirectly as a gene. The advantage of giving VEGF or
bFGF as the protein is the ability to achieve precise dosing
at known intervals, while the disadvantage is that a large
quantity is required because of its short half-life. Delivering
the genetic material to host cells that take it up and then
produce the growth factor has an innate elegance. Although
this approach theoretically enables continuous production of
the growth factor, the amount and duration of production is
unknown and unregulated. Numerous issues remain con-
cerning the most efficacious and safest method for packag-
ing and delivering the growth factors (5).
ANGIOGENESIS IN ANIMAL MODELS OF ISCHEMIA
Animal studies have established the principle that collateral
function improves after administrating angiogenic growth
factors using different methods of packaging and delivery.
In dogs given intracoronary injections of bFGF, myocar-
dial angiogenesis had been reported, as evidenced by in-
creased synthesis of endothelial cell DNA, increased collat-
eral vessel density and improved regional blood flow (8).
Vascular endothelial growth factor165 is also effective. When
it was infused continuously over four weeks into the
myocardium adjacent to the site of an ameroid constrictor
placed on the circumflex artery of swine, blood flow to this
region increased at rest and during stress (9). Intravenous
injection of these growth factors may not induce angiogen-
esis as effectively, because of the large volume of dilution
and first pass uptake by the lungs (5).
Using the model of hind limb ischemia in the rabbit,
intramuscular bFGF (10) and acidic fibroblast growth factor
(11), and also intramuscular and intra-arterial VEGF165
(12,13), stimulate angiogenesis documented by increased
collateral vessel density on angiography, higher perfusion
pressure in the distal vessels and increased blood flow.
Increased vascular endothelial proliferation also occurs.
CLINICAL STUDIES OF ANGIOGENESIS IN CAD
Observations from four uncontrolled, nonrandomized stud-
ies have demonstrated safety and feasibility of VEGF and
bFGF with some suggestions of efficacy. Intramyocardial
injections of VEGF through a mini-thoracotomy were done
in five patients with refractory angina not amenable to
surgical or interventional therapy (14). At the time of bypass
graft surgery, DNA encoding VEGF121 carried by an
adenoviral vector was administered into the myocardium of
a nonbypassable coronary artery in 21 patients (15), and
microcapsules containing FGF were implanted into the
epicardial fat of a diseased vessel in eight patients (16). At
the time of angiography, 14 patients received either low or
high dose VEGF by selective infusion into a coronary artery
over 20 min (17). Each of these studies reported reduction
in angina and less ischemia or increased collateral vessels
assessed by nuclear study, magnetic resonance imaging or
coronary angiography. Because of the small number of
patients and lack of control groups, the results from these
studies need to be considered cautiously.
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Two randomized, controlled series of angiogenic growth
factors in individuals with CAD have been reported. Forty
patients received an intramyocardial injection of bFGF or
placebo into the region of the anastomosis of the internal
mammary graft to the left anterior descending artery (18).
Angiography performed 12 weeks later was interpreted as
showing arterial collaterals in the area of the bFGF injec-
tion. No long-term follow-up or objective evidence of
improved blood flow was reported. The second study
randomized patients to receive one of three doses of
VEGF165 or placebo intracoronary followed by intravenous
infusion on days 3, 6 and 9 (19). The exercise time of the
treated and placebo group improved equivalently. The study
was terminated due to the absence of a positive effect of the
VEGF (5). Although the lack of benefit may reflect the
route of administration chosen (IV), the improvement in
the nontreated patients noted in this study reinforces the
crucial need for a placebo-controlled group in clinical
studies.
CLINICAL STUDIES OF ANGIOGENESIS
IN PERIPHERAL VASCULAR DISEASE
Isner and colleagues (20) first injected naked human plas-
mid DNA encoding VEGF165 into 10 affected limbs of nine
patients. Vascular endothelial growth factor expression
peaked from one to three weeks after the gene transfer.
After four weeks, the ankle-brachial index increased by 30%
(0.33 6 0.05 to 0.43 6 0.04). This improvement was
sustained at 12 weeks. Blood flow measured by magnetic
resonance imaging improved in 8 of 10 limbs with angio-
graphic evidence of new collateral formation observed in 7
of 10 extremities.
The article by Lazarous et al. (21) in this issue of the
Journal is the first report of bFGF administered intra-
arterially in humans. In this phase I study, subjects with
intermittent claudication were randomly assigned to placebo
group (n 5 6) or bFGF at 10 mg/kg once (n 5 4), 30 mg/kg
once (n 5 5) or 30 mg/kg given on two consecutive days
(n 5 4). The agent was infused into the artery of the most
severely affected leg. The individuals were monitored closely
over time for known and potential side effects of bFGF. The
rate of infusion was adjusted to avoid hypotension that
occurred in the first subject that received bFGF. A second
subject had a fall in platelet count from a low normal value
(150,000/mm3 to 124,000/mm3), while a third person with
no history of arrhythmia developed atrial fibrillation with
spontaneous conversion 12 h later.
The study protocol was amended to assess possible effects
of bFGF on lower extremity flow in the two high-dose
groups using strain gauge plethysmography. At six months,
the treated subjects in the 30 mg/kg once group had a near
doubling of flow, while the 30 mg/kg twice group had a
greater than three-fold increase over baseline lower extrem-
ity flow.
As physicians interested in the potential benefits of
therapeutic angiogenesis, we were invited to comment on
this report. We share two contrasting feelings. For several
reasons, one feeling is very positive. First, this is a fascinat-
ing field of investigation that we hope will have a major
beneficial impact on management of ischemic vascular
disease. Second, this is an experienced group of investigators
who have done excellent work on therapeutic angiogenesis
in animal models of ischemia (5,8). They are now appro-
priately applying their expertise to clinical studies. Third,
these initial safety, tolerability and pharmacokinetic data for
bFGF in humans are reassuring. The authors present these
data objectively and clearly state adverse effects without
judgment. Fourth, the inclusion of a placebo control is a
major strength.
On the other hand, this article causes us some misgivings,
especially the estimates of lower extremity blood flow by
venous occlusive plethysmography. First, the value of these
results may be compromised because the number of patients
is so small, and major differences exist between the placebo
and treatment groups. The placebo group is older and has
more subjects with hypertension and diabetes. Diabetics
have a different distribution of peripheral arterial disease
with more extensive calcifications (22). The treatment
group had more peripheral vascular surgery done.
Second, the suggestion that bFGF causes a two- to
three-fold increase in baseline flow is astonishing! Since
this experiment has never been done, the results could be
correct. However, the calf blood flow estimated by
plethysmography is quite suspect (see comments to fol-
low). One could argue that the authors need to be quite
certain their data are correct and verifiable by additional
estimates of blood flow before such extraordinary results
are accepted.
Third, plethysmography may not adequately estimate
lower extremity blood flow. Plethysmography has not
been used for decades in outcome studies of peripheral
vascular disease (22). Since the technique was developed
for use in the forearm, the calculation of forearm volume
may not apply to the leg with its different and more
diverse shapes. Consistent venous occlusive flow mea-
surements are not easy to obtain, and variability at best is
620% between measurements. These concerns may be
evident in the control group with an unexplained 67%
increase in flow above baseline at one month, a value
similar to the treatment group, only to return to near
baseline at six months. Other techniques to support the
finding from plethysmography could have been included.
Ankle-brachial or toe systolic pressure index at rest and
after exercise, total treadmill walk time and treadmill
walk time to claudication are the most widely accepted
measures of outcome in prospectively randomized
placebo-controlled groups with arterial insufficiency of
the lower extremities (22). Some of this information,
available at baseline, unfortunately, was not reported after
treatment.
1246 Pantely et al. JACC Vol. 36, No. 4, 2000
Editorial Comment October 2000:1245–7
CONCLUSIONS
Therapeutic angiogenesis has great potential for treating
individuals suffering from tissue ischemia. More work is
needed to realize that possibility. Safety, tolerability and
pharmacokinetic studies of potential agents, such as the
report of Lazarous et al. (21), are an essential first step in
applying this technology to patients. On the other hand,
publication of preliminary results purporting to show in-
credible benefit is not without scientific risk. Such reports
often prove to be incorrect, due, in part, to data in a small
number of subjects that are insufficient to support the
claims. Therapeutic angiogenesis is an important area,
certainly worthy of the highest quality scientific studies. The
uniqueness of its potential should not alter that principle.
We look forward to reading results of such studies from this
group as well as others that have contributed so much to our
understanding of angiogenesis.
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